Oral lactoferrin for the prevention of sepsis and necrotizing enterocolitis in premature infants

Cochrane Database of Systematic Reviews

Volumn , Issue 2, 2008, Pages

  Mohan, Pammi ^a   Abrams, Steven A ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b CHILDREN S NUTRITION RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LACTOFERRIN; PLACEBO;

ADVERSE OUTCOME; ARTIFICIAL MILK; BIRTH WEIGHT; BREAST MILK; CLINICAL TRIAL; COCHRANE LIBRARY; DATA COLLECTION METHOD; DIET SUPPLEMENTATION; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; GASTRIC SUCTION; GESTATIONAL AGE; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; META ANALYSIS; NECROTIZING ENTEROCOLITIS; NEWBORN SEPSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITIVE END EXPIRATORY PRESSURE; PREMATURITY; PROPHYLAXIS; REVIEW; SYSTEMATIC REVIEW; TREATMENT DURATION; VERY LOW BIRTH WEIGHT;

EID: 44949103346     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD007137     Document Type: Review

References (33)

1. Adams-Chapman 2006 Adams-Chapman I, Stoll BJ. Neonatal infection and long-term neurodevelopmental outcome in the preterm infant. Current Opinion in Infectious Diseases 2006;19:290-7.
2. Alderson 2005 Alderson P, Green S, Higgins JPT, editors. Cochrane Reviewer's Handbook 4.2.3 [updated Nov 2004]. Cochrane Database of Systematic Reviews. Chichester, U.K.: John Wiley & Sons (Ltd), 2005.
3. Artym 2004 Artym J, Zimecki M, Kruzel ML. Enhanced clearance of Escherichia coli and Staphylococcus aureus in mice treated with cyclophosphamide and lactoferrin. International Immunopharmacology 2004;4:1149-57.
4. Bell 1978 Bell MJ, Ternberg JL, Feigin RD, Keating JP, Marshall R, Barton L, Brotherton T. Neonatal necrotising enterocolitis. Therapeutic decisions based upon clinical staging. Annals of Surgery 1978;187:1-7.
5. Bellamy 1992 Bellamy W, Takase M, Wakabayashi H, Kawase K, Tomita M. Antibacterial spectrum of lactoferricin B, a potent bactericidal peptide derived from the N-terminal region of bovine lactoferrin. Journal of Applied Bacteriology 1992;73:472-9.
6. Bhutta 1997 Bhutta ZA. Neonatal infections. Current Opinion in Pediatrics 1997;9:133-40.
7. Blackwell 1997 Blackwell TS, Christman JW. The role of nuclear factor-kappa B in cytokine gene regulation. American Journal of Respiratory Cell and Molecular Biology 1997;17:3-9.
8. Buccigrossi 2007 Buccigrossi V, de Marco G, Bruzzese E, Ombrato L, Bracale I, Polito G, Guarino A. Lactoferrin induces concentration-dependent functional modulation of intestinal proliferation and differentiation. Pediatric Research 2007;61:410-4.
9. Edde 2001 Edde L, Hipolito RB, Hwang FF, Headon DR, Shalwitz RA, Sherman MP. Lactoferrin protects neonatal rats from gut-related systemic infection. American Journal of Physiology. Gastrointestinal and Liver Physiology 2001;281:G1140-50.
10. Gifford 2005 Gifford JL, Hunter HN, Vogel HJ. Lactoferricin: a lactoferrin-derived peptide with antimicrobial, antiviral, antitumor and immunological properties. Cellular and Molecular Life Sciences 2005;62:2588-98.
11. Hayes 2006 Hayes TG, Falchook GF, Varadhachary GR, Smith DP, Davis LD, Dhingra HM, Hayes BP, Varadhachary A. Phase I trial of oral talactoferrin alfa in refractory solid tumors. Investigational New Drugs 2006;24:233-40.
12. Iwasa 2002 Iwasa M, Kaito M, Ikoma J, Takeo M, Imoto I, Adachi Y, Yamauchi K, Koizumi R, Teraguchi S. Lactoferrin inhibits hepatitis C virus viremia in chronic hepatitis C patients with high viral loads and HCV genotype 1b. American Journal of Gastroenterology 2002;97:766-7.
13. Kuipers 1999 Kuipers ME, de Vries HG, Eikelboom MC, Meijer DK, Swart PJ. Synergistic fungistatic effects of lactoferrin in combination with antifungal drugs against clinical Candida isolates. Antimicrobial Agents and Chemotherapy 1999;43:2635-41.
14. Lawn 2006 Lawn JE, Wilczynska-Ketende K, Cousens SN. Estimating the causes of 4 million neonatal deaths in the year 2000. International Journal of Epidemiology 2006;35:706-18.
15. Leitch 1999 Leitch EC, Willcox MD. Lactoferrin increases the susceptibility of S. epidermidis biofilms to lysozyme and vancomycin. Current Eye Research 1999;19:12-9.
16. Levy 1998 Levy SB. Antimicrobial resistance: Bacteria on the defence. Resistance stems from misguided efforts to try to sterilize our environment. BMJ 1998;317:612-13.
17. Lin 2006 Lin PW, Stoll BJ. Necrotizing enterocolitis. Lancet 2006;368:1271-83.
18. Neish 2004 Neish AS. Molecular aspects of intestinal epithelial cell-bacterial interactions that determine the development of intestinal inflammation. Inflammatory Bowel Diseases 2004;10:159-68.
19. Nibbering 2001 Nibbering PH, Ravensbergen E, Welling MM, van Berkel LA, van Berkel PH, Pauwels EK, Nuijens JH. Human lactoferrin and peptides derived from its N terminus are highly effective against infections with antibiotic-resistant bacteria. Infection and Immunity 2001;69:1469-76.
20. Speer 1999 Speer CP. Inflammatory mechanisms in neonatal chronic lung disease. European Journal of Pediatrics 1999;158(suppl):S18- 22.
21. Stoll 2002 Stoll BJ, Hansen N, Fanaroff AA, Wright LL, Carlo WA, Ehrenkranz RA, Lemons JA, Donovan EF, Stark AR, Tyson JE, Oh W, et al.Late-onset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal Research Network. Pediatrics 2002;110:285-91.
22. Stoll 2004a Stoll BJ, Hansen NI, Adams-Chapman I, Fanaroff AA, Hintz SR, Vohr B, Higgins RD. Neurodevelopmental and growth impairment among extremely low-birth-weight infants with neonatal infection. Jama 2004;19:2357-65.
23. Stoll 2004b Stoll BJ. Infections of the neonatal infant. In: Behrman RE KR, Jenson HB editor(s). Nelson's Textbook of Pediatrics. Philadelphia: Saunders, 2004:623-640.
24. Stoll 2005 Stoll BJ, Hansen NI, Higgins RD, Fanaroff AA, Duara S, Goldberg R, Laptook A, Walsh M, Oh W, Hale E. Very low birth weight preterm infants with early onset neonatal sepsis: the predominance of gram-negative infections continues in the National Institute of Child Health and Human Development Neonatal Research Network, 2002-2003. Pediatric Infectious Disease Journal 2005;24:635-9.
25. Tanaka 1999 Tanaka K, Ikeda M, Nozaki A, Kato N, Tsuda H, Saito S, Sekihara H. Lactoferrin inhibits hepatitis C virus viremia in patients with chronic hepatitis C: a pilot study. Japanese Journal of Cancer Research 1999;90:367-71.
26. Togawa 2002 Togawa J, Nagase H, Tanaka K, Inamori M, Umezawa T, Nakajima A, Naito M, Sato S, Saito T, Sekihara H. Lactoferrin reduces colitis in rats viamodulation of the immune systemand correction of cytokine imbalance. American Journal of Physiology. Gastrointestinal and Liver Physiology 2002;283:G187-95.
27. Tomita 2002 Tomita M, Wakabayashi H, Yamauchi K, Teraguchi S, Hayasawa H. Bovine lactoferrin and lactoferricin derived from milk: production and applications. Biochemistry and Cell Biology 2002;80:109-12.
28. Trumpler 1989 Trumpler U, Straub PW, Rosenmund A. Antibacterial prophylaxis with lactoferrin in neutropenic patients. European Journal of Clinical Microbiology and Infectious Diseases 1989;8:310-3.
29. Valenti 2005 Valenti P, Antonini G. Lactoferrin: an important host defence against microbial and viral attack. Cellular and Molecular Life Sciences 2005;62:2576-87.
30. Venkatesh 2007 Venkatesh M, Pham D, Kong L, Weisman L. Prophylaxis with lactoferrin, a novel antimicrobial agent, enhances survival in a neonatal rat model of co-infection. Advances in Therapy 2007;24:941-54.
31. Volpe 1995 Volpe JJ. Neurology of the Newborn. 3rd Edition. Philadelphia, London: WB Saunders, 1995.
32. Zagulski 1989 Zagulski T, Lipinski P, Zagulska A, Broniek S, Jarzabek Z. Lactoferrin can protect mice against a lethal dose of Escherichia coli in experimental infection in vivo. British Journal of Experimental Pathology 1989;70:697-704.
33. Zaidi 2005 Zaidi AKM, Huskins WC, Thaver D, Bhutta ZA, Abbas Z, Goldmann DA. Hospital-acquired neonatal infections in developing countries. Lancet 2005;365:1175-88.